Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

1. Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.Journal of cancer research and clinical oncology · 2022
   Pooled it
2. Case Report: Exceptional survival with immunotherapy in a patient withFrontiers in immunology · 2026
   Article
3. A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
   Article
4. Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer: Single-Institution Experience.Cancer research and treatment · 2024
   Article
5. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Frontiers in immunology · 2024
   Review
6. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation.Frontiers in oncology · 2024
   Review
7. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).Translational lung cancer research · 2023
   Article
8. Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer andTranslational lung cancer research · 2023
   Article
9. Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion.Current oncology (Toronto, Ont.) · 2023
   Article
10. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.Thoracic cancer · 2023
    Review
11. Real-World Response and Outcomes in Patients With NSCLC WithJTO clinical and research reports · 2023
    Article
12. Translational lung cancer research · 2023
    Review
13. [Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
    Article
14. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.JTO clinical and research reports · 2023
    Article
15. Advances in the management of non-small-cell lung cancer harbouringTherapeutic advances in medical oncology · 2023
    Review
16. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.Cancer medicine · 2023
    Article
17. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.Annals of translational medicine · 2022
    Review
18. [Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer 
with EGFR Mutation].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022
    Article
19. EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives.Biomarker research · 2022
    Review
20. JTO clinical and research reports · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

23 authors at 5 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as